Delcath Systems, Inc. income statement
In fiscal 2025, Delcath Systems, Inc. reported revenue of $85.2m, up 129.1% on the year before, operating income of $660,000 (a 0.8% margin) and net income of $2.7m, or $0.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 | 2 | 4 | 3 | 2 | 37 | 85 | 95 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 6 | 12 | 12 |
| Gross profit | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 31 | 73 | 83 |
| Research and development | 18 | 25 | 26 | 13 | 4 | 6 | 14 | 19 | 18 | 14 | 29 | 38 |
| Selling, general and administrative | 13 | 21 | 28 | 21 | 16 | 10 | 14 | 17 | 22 | 30 | 44 | 47 |
| Operating income | −31 | −46 | −54 | −33 | −19 | −15 | −25 | −34 | −38 | −12 | 1 | −2 |
| Interest expense | — | — | — | — | — | 0 | — | — | — | — | — | — |
| Income before tax | — | — | — | −30 | −17 | −15 | −26 | −37 | −48 | −26 | 4 | 1 |
| Income tax | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Net income | −47 | −31 | −52 | −30 | −17 | −15 | −26 | −37 | −48 | −26 | 3 | 1 |
| Diluted EPS | −$840.00 | −$476.00 | −$9478.00 | −$5.10 | −$1.84 | −$637.00 | −$3.59 | −$4.12 | −$2.94 | −$0.93 | $0.07 | $0.01 |
| Diluted shares (average) | 56m | 65m | — | — | 14m | 23m | 7m | 9m | 16m | 29m | 40m | 39m |
| EBITDA | −30 | −45 | −53 | −32 | −18 | −15 | −24 | −34 | −38 | −12 | 1 | −1 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11 | 15 | 20 | 24 | 21 | 21 | 25 | 29 |
| Cost of revenue | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 3 |
| Gross profit | 10 | 13 | 17 | 21 | 18 | 18 | 21 | 26 |
| Research and development | 4 | 3 | 5 | 7 | 8 | 9 | 10 | 10 |
| Selling, general and administrative | 7 | 7 | 11 | 11 | 10 | 11 | 13 | 13 |
| Operating income | −1 | 3 | 1 | 3 | −0 | −2 | −2 | 2 |
| Income before tax | 2 | −3 | 1 | 3 | 0 | −1 | −1 | 3 |
| Income tax | 0 | 0 | 0 | 1 | −0 | 1 | 0 | 0 |
| Net income | 2 | −3 | 1 | 3 | 1 | −2 | −1 | 3 |
| Diluted EPS | $0.06 | −$0.09 | $0.03 | $0.07 | $0.02 | −$0.05 | −$0.03 | $0.07 |
| EBITDA | −1 | 3 | 1 | 3 | −0 | −2 | −2 | 2 |
Compare with peers
- Iradimed Corp income statement
- Ceribell, Inc. income statement
- Pulmonx Corp income statement
- Sight Sciences, Inc. income statement
- Xtant Medical Holdings, Inc. income statement
Head to head: DCTH vs IRMDCBLL vs DCTHDCTH vs LUNG
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies